Literature DB >> 22293084

Ivacaftor potentiation of multiple CFTR channels with gating mutations.

Haihui Yu1, Bill Burton, Chien-Jung Huang, Jennings Worley, Dong Cao, James P Johnson, Art Urrutia, John Joubran, Sheila Seepersaud, Katherine Sussky, Beth J Hoffman, Fredrick Van Goor.   

Abstract

BACKGROUND: The investigational CFTR potentiator ivacaftor (VX-770) increased CFTR channel activity and improved lung function in subjects with CF who have the G551D CFTR gating mutation. The aim of this in vitro study was to determine whether ivacaftor potentiates mutant CFTR with gating defects caused by other CFTR gating mutations.
METHODS: The effects of ivacaftor on CFTR channel open probability and chloride transport were tested in electrophysiological studies using Fischer rat thyroid (FRT) cells expressing different CFTR gating mutations.
RESULTS: Ivacaftor potentiated multiple mutant CFTR forms with defects in CFTR channel gating. These included the G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P and G1349D CFTR gating mutations.
CONCLUSION: These in vitro data suggest that ivacaftor has a similar effect on all CFTR forms with gating defects and support investigation of the potential clinical benefit of ivacaftor in CF patients who have CFTR gating mutations beyond G551D.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293084     DOI: 10.1016/j.jcf.2011.12.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  147 in total

1.  Ivacaftor.

Authors:  Pamela B Davis; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694

2.  Conformational changes relevant to channel activity and folding within the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator.

Authors:  Rhea P Hudson; P Andrew Chong; Irina I Protasevich; Robert Vernon; Efrat Noy; Hermann Bihler; Jian Li An; Ori Kalid; Inbal Sela-Culang; Martin Mense; Hanoch Senderowitz; Christie G Brouillette; Julie D Forman-Kay
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 3.  Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Authors:  Versha Prakash; Marc Moore; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

Review 4.  Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2016-08       Impact factor: 9.546

5.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

6.  PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Ellen M McDonagh; John P Clancy; Michelle Whirl Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-01       Impact factor: 2.089

Review 7.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

Review 8.  Nonequilibrium gating of CFTR on an equilibrium theme.

Authors:  Kang-Yang Jih; Tzyh-Chang Hwang
Journal:  Physiology (Bethesda)       Date:  2012-12

9.  Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Authors:  Puay-Wah Phuan; Jung-Ho Son; Joseph-Anthony Tan; Clarabella Li; Ilaria Musante; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Mark J Kurth; Luis J Galietta; Peter M Haggie; Alan S Verkman
Journal:  J Cyst Fibros       Date:  2018-06-12       Impact factor: 5.482

10.  Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).

Authors:  Elizabeth Matthes; Julie Goepp; Graeme W Carlile; Yishan Luo; Kurt Dejgaard; Arnaud Billet; Renaud Robert; David Y Thomas; John W Hanrahan
Journal:  Br J Pharmacol       Date:  2016-01-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.